Ligand Pharmaceuticals Inc
0 products tracked · names used in filings: Ligand Pharmaceuticals Inc
Upcoming milestones
Ligand Pharmaceuticals Inc: PDUFA target action date
Ligand Pharmaceuticals Inc (LGND); "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027."; filed 2026-10-29 · source
Recent milestones
Tzield: PDUFA target action date (expand age indication to patients as young as one year old to delay onset of stage 3 T1D in patients diagnosed with stag)
Ligand Pharmaceuticals Inc (LGND); teplizumab; sBLA; status: set; "…n January 5, 2026, Sanofi announced the FDA accepted for priority review the sBLA for Tzield to expand the current age indication from eight years and above, to as young as one year old and above to delay the onset of stage 3 T1D in patients diagnosed with stage 2 T1D. The sBLA is supported by the positive interim…"; filed 2026-02-26 · source
Filspari: PDUFA target action date (focal segmental glomerulosclerosis (FSGS))
Ligand Pharmaceuticals Inc (LGND); sparsentan; sNDA; status: extended; "The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026."; filed 2026-02-26 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.